"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 3 | 4 | 7 |
| 1999 | 4 | 2 | 6 |
| 2000 | 1 | 8 | 9 |
| 2001 | 7 | 2 | 9 |
| 2002 | 5 | 6 | 11 |
| 2003 | 8 | 6 | 14 |
| 2004 | 8 | 5 | 13 |
| 2005 | 9 | 6 | 15 |
| 2006 | 5 | 9 | 14 |
| 2007 | 10 | 4 | 14 |
| 2008 | 8 | 2 | 10 |
| 2009 | 13 | 9 | 22 |
| 2010 | 11 | 4 | 15 |
| 2011 | 13 | 13 | 26 |
| 2012 | 10 | 6 | 16 |
| 2013 | 9 | 5 | 14 |
| 2014 | 15 | 2 | 17 |
| 2015 | 22 | 8 | 30 |
| 2016 | 10 | 13 | 23 |
| 2017 | 25 | 9 | 34 |
| 2018 | 22 | 7 | 29 |
| 2019 | 19 | 8 | 27 |
| 2020 | 20 | 15 | 35 |
| 2021 | 20 | 15 | 35 |
| 2022 | 4 | 34 | 38 |
| 2023 | 6 | 25 | 31 |
| 2024 | 12 | 8 | 20 |
| 2025 | 17 | 2 | 19 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i13-i16.
-
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i6-i12.
-
Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study. Clin Infect Dis. 2025 Oct 06; 81(3):623-633.
-
Clinician Preferences for Oseltamivir Use in Children With Influenza in the Outpatient Setting. Pediatrics. 2025 Sep 01; 156(3).
-
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clin Infect Dis. 2025 Aug 01; 81(1):190-197.
-
Role of Wound Care in Management of Severe Verrucous Papular Lesions Due to Mpox Infection: A Case Report. Adv Skin Wound Care. 2025 Sep 01; 38(8):E69-E72.
-
Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys. Nat Commun. 2025 Jul 11; 16(1):6437.
-
Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemp Clin Trials. 2025 Oct; 157:107995.
-
Antiviral Prescription in Children With Influenza in US Emergency Departments: New Vaccine Surveillance Network (NVSN), 2016-2020. Influenza Other Respir Viruses. 2025 Jun; 19(6):e70124.
-
BTP2 restricts Tulane virus and human norovirus replication independent of store-operated calcium entry. J Virol. 2025 Jun 17; 99(6):e0044425.